Xiaolei Li1,
Suzhao Zhang2 
,
Gengliang Zhang1,
Jun Yuan2,
Shiling Rong1,
Meng Wang3,
Jie Wu1,
Xiaoci Feng1,
Huan He1,
Linying Tian1,
Weihua Xue2
For correspondence:- Suzhao Zhang Email: SydneyGrimescdj@yahoo.com Tel:+8631169095105
Accepted: 25 November 2019 Published: 30 December 2019
Citation: Li X, Zhang S, Zhang G, Yuan J, Rong S, Wang M, et al. 3-Cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one ameliorates diabetic peripheral neuropathy in type 2 diabetes mellitus rats via PI3K/Akt signaling pathway. Trop J Pharm Res 2019; 18(12):2509-2514 doi: 10.4314/tjpr.v18i12.7
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the curative effects of 3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one (CHMP) on streptozotocin (STZ)-induced model of diabetic SD rats, and the underlying mechanism.
Method: Diabetes was induced in rats using single intraperitoneal injection of STZ. Subsequently, diabetic and non-diabetic rats were randomly grouped into five experimental groups. Six weeks after the STZ-injection, the diabetic animals were orally administered test compound (CHMP) at two doses of 10 and 20 mg/kg body weight for 6 weeks. Thereafter, the rats were anesthetised, and body weight, blood sugar, and motor nerve conduction velocity (MNCV) were determined. Moreover, real time-polymerase chain reaction (RT-PCR) and western blot analysis were used to assay the ex
Results: Treatment of diabetic rats with CHMP significantly reduced levels of fasting blood glucose and enhanced average rat body weight, relative to diabetic control (p F6; 0.05). Motor nerve conduction velocity (MNCV) was remarkably increased in CHMP-treated rats (54.2 ± 2.2), when compared to the diabetic control rats (46 ± 4.1, p < 0.01). Results from RT-PCR and western blot indicated increased ex
Conclusion: These findings show that CHMP may be beneficial in the management of diabetic neuropathy.
Archives
News Updates
Fulltext in PDF